FLT3 and acute myeloid leukemia: The differential response of MV4:11 and MOLM13 cells to combination treatment with revumenib and tamibarotene suggests different genetic programs, despite a comparable molecular setting including KMT2Ar and FLT3-ITD in both AML cell models.